AMGN's Repatha (#msg-114390191), which is already approved in the EU and has an FDA PDUFA date of 8/27/15; and PFE's Bococizumab (#msg-99602642), which is in phase-3.
Recent literature seems to suggest that Amarin's Vascepa, with its 96% EPA content, is effective in reducing cholesterol oxidation, an indication that may be more important than simply reducing cholesterol. That currently would be off-label indication.
You might page through this person's list for any journal articles that focus on undesirable nature of cholesterol Oxidation and consequent contribution to plaque formation:
News 
Market Data 
Discover 
AI
